The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
Silverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,334
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 773
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.03.001 · Cited by 622
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results
Wang, C.-Y., Liu, P.-Y., & Liao, J. K. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.11.004 · Cited by 593
Pleiotropic Effects of Statins - Basic Research and Clinical Perspectives -
Zhou, Q., & Liao, J. K. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0110 · Cited by 567
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Gylling, H., Plat, J., Turley, S., Ginsberg, H. N., Ellegård, L., Jessup, W., Jones, P. J., Lütjohann, D., Maerz, W., Masana, L., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.11.043 · Cited by 529
High-Sensitivity C-Reactive Protein and Cardiovascular Disease
Yousuf, O., Mohanty, B. D., Martin, S. S., Joshi, P. H., Blaha, M. J., Nasir, K., Blumenthal, R. S., & Budoff, M. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.016 · Cited by 494
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.037 · Cited by 486
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.07.007 · Cited by 462
Nut Consumption and Blood Lipid Levels: A Pooled Analysis of 25 Intervention Trials
Sabaté, J. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.79 · Cited by 422
Strippoli, G. F. M., Navaneethan, S. D., Johnson, D. W., Perkovic, V., Pellegrini, F., Nicolucci, A., & Craig, J. C. (2008) · BMJ · doi:10.1136/bmj.39472.580984.ae · Cited by 402
Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368
Self-citationBeyond Low-Density Lipoprotein Cholesterol
Arsenault, B. J., Rana, J. S., Stroes, E. S. G., Després, J.-P., Shah, P. K., Kastelein, J. J. P., Wareham, N. J., Boekholdt, S. M., & Khaw, K.-T. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.057 · Cited by 342
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub2 · Cited by 331
Cannon, C. P., Giugliano, R. P., Blazing, M. A., Harrington, R. A., Peterson, J. L., Sisk, C. M., Strony, J., Musliner, T. A., McCabe, C. H., Veltri, E., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.07.023 · Cited by 299
Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Zhou, Q., & Liao, J. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315684 · Cited by 294
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy
Grundy, S. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2005 · Cited by 287
Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262
“Nevertheless, a clear and approximately linear association is present, suggesting that a lower on-treatment Apo B concentration is associated with a lower CHD event rate, as has been shown previously for LDL-C and non-HDL-C.(161,162) The association is particularly robust for statin therapy, which has the largest evid…”
BackgroundPandor, A., Ara, R. M., Tumur, I., Wilkinson, A. J., Paisley, S., Duenas, A., Durrington, P. N., & Chilcott, J. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02062.x · Cited by 228
VanWagner, L. B., Bhave, M., Te, H. S., Feinglass, J., Alvarez, L., & Rinella, M. E. (2012) · Hepatology · doi:10.1002/hep.25855 · Cited by 220
“Left heart catheterization performed 51 (44) 48 (38) 0.”
BackgroundChiavaroli, L., Lee, D., Ahmed, A., Cheung, A., Khan, T. A., Blanco, S., Mejia, Mirrahimi, A., Jenkins, D. J. A., Livesey, G., et al. (2021) · BMJ · doi:10.1136/bmj.n1651 · Cited by 215
Viguiliouk, E., Kendall, C. W., Kahleová, H., Rahelić, D., Salas-Salvadó, J., Choo, V. L., Mejia, S. B., Stewart, S. E., Leiter, L. A., Jenkins, D. J., et al. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.05.032 · Cited by 201
Musa-Veloso, K., Poon, T. H., Elliot, J. A., & Chung, C. (2011) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2011.02.001 · Cited by 195
“There is a consistent linear relationship between reductions in LDL-CH and reduced risk of coronary events [136,137,138]; specifically, for every 1% reduction in LDL-CH concentration, there is a corresponding 1–2% decrease in the risk of CHD [138,139].”
BackgroundHa, V., Sievenpiper, J. L., de Souza, R. J., Jayalath, V. H., Mirrahimi, A., Agarwal, A., Chiavaroli, L., Mejia, S. B., Sacks, F. M., Di Buono, M., et al. (2014) · Canadian Medical Association Journal · doi:10.1503/cmaj.131727 · Cited by 194
Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase
Würtz, P., Wang, Q., Soininen, P., Kangas, A. J., Fatemifar, G., Tynkkynen, T., Tiainen, M., Perola, M., Tillin, T., Hughes, A. D., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.060 · Cited by 188
Sabatine, M. S., Giugliano, R. P., Keech, A., Honarpour, N., Wang, H., Liu, T., Wasserman, S. M., Scott, R., Sever, P. S., & Pedersen, T. R. (2016) · American Heart Journal · doi:10.1016/j.ahj.2015.11.015 · Cited by 176
F. Piepoli, M. (2017) · International Journal of Behavioral Medicine · doi:10.1007/s12529-016-9583-6 · Cited by 162
“Data indicate that combination therapy with ezetimibe also brings a benefit that is in line with the Cholesterol Treatment Trialists’ (CTT) Collaboration meta-analysis supporting the notion that LDL-C reduction is key to the achieved benefit independent of the approach used [353, 375].”
Li, S. S., Blanco Mejia, S., Lytvyn, L., Stewart, S. E., Viguiliouk, E., Ha, V., de Souza, R. J., Leiter, L. A., Kendall, C. W. C., Jenkins, D. J. A., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006659 · Cited by 139
Robinson (2012) · doi:10.1016/j.amjcard.2012.07.007 · Cited by 137
Beyond Low-Density Lipoprotein Cholesterol
Mudd, J. O., Borlaug, B. A., Johnston, P. V., Kral, B. G., Rouf, R., Blumenthal, R. S., & Kwiterovich, P. O. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.045 · Cited by 136
Ray, K. K., Ginsberg, H. N., Davidson, M. H., Pordy, R., Bessac, L., Minini, P., Eckel, R. H., & Cannon, C. P. (2016) · Circulation · doi:10.1161/circulationaha.116.024604 · Cited by 127
Huijgen, R., Kindt, I., Verhoeven, S. B. J., Sijbrands, E. J. G., Vissers, M. N., Kastelein, J. J. P., & Hutten, B. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009220 · Cited by 124
Sahebkar, A., Di Giosia, P., Stamerra, C. A., Grassi, D., Pedone, C., Ferretti, G., Bacchetti, T., Ferri, C., & Giorgini, P. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12905 · Cited by 116
Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies
Olshansky, B., Chung, M. K., Budoff, M. J., Philip, S., Jiao, L., Doyle, Jr., Copland, C., Giaquinto, A., Juliano, R. A., & Bhatt, D. L. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa117 · Cited by 103
Viguiliouk, E., Blanco Mejia, S., Kendall, C. W. C., & Sievenpiper, J. L. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13312 · Cited by 101
Curing atherosclerosis should be the next major cardiovascular prevention goal
Robinson, J. G., & Gidding, S. S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.009 · Cited by 87
“benefits of statins are directly proportional to the degree of LDL-C lowering and consistent with the degree of ASCVD event reduction observed with other LDL-C–lowering approaches such as ileal bypass surgery, bile acid sequestrants, and diet (35).”
ResultSelf-citationHuijgen, R., Abbink, E. J., Bruckert, E., Stalenhoef, A. F. H., Imholz, B. P. M., Durrington, P. N., Trip, M. D., Eriksson, M., Visseren, F. L. J., Schaefer, J. R., et al. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.04.014 · Cited by 80
Pleiotropic Effects of Statins: Evidence Against Benefits Beyond LDL-Cholesterol Lowering
Pedersen, T. R. (2010) · American Journal Cardiovascular Drugs · doi:10.2165/1158822-s0-000000000-00000 · Cited by 74
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
“detrimental effects.(4) With the recent approval of inhibitors of proprotein convertase subtilisin kexin 9 (PCSK9), a review of all nonstatin LDL cholesterol–lowering therapies was timely.”
BackgroundSelf-citationOgier, N., Amiot, M.-J., Georgé, S., Maillot, M., Mallmann, C., Maraninchi, M., Morange, S., Lescuyer, J.-F., Peltier, S. L., & Cardinault, N. (2013) · European Journal of Nutrition · doi:10.1007/s00394-012-0357-x · Cited by 49
Repurposing of statins via inhalation to treat lung inflammatory conditions
Bradbury, P., Traini, D., Ammit, A. J., Young, P. M., & Ong, H. X. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.005 · Cited by 38
Metadata
- Authors
- Robinson, J. G., Smith, B., Maheshwari, N., & Schrott, H.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2005-11
- Volume
- 46
- Issue
- 10
- Pages
- 1855-1862
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2142283630
- Cited by
- 407
- References
- 105
- FWCI
- 33.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.